Astria Therapeutics, Inc. 4/A SEC Filings

Filed On	Filing
21 Jun 2022	Form 4/A: Kishbauch Michael D, Director Granted 8,333 Stock Option (right to buy)
21 Jun 2022	Form 4/A: Bate Kenneth, Director Granted 8,333 Stock Option (right to buy)
21 Jun 2022	Form 4/A: Violin Jonathan, Director Granted 8,333 Stock Option (right to buy)
21 Jun 2022	Form 4/A: Beck Joanne T., Director Granted 8,333 Stock Option (right to buy)
21 Jun 2022	Form 4/A: Cole Hugh M, Director Granted 8,333 Stock Option (right to buy)
21 Jun 2022	Form 4/A: Lapointe Anthony Gregg, Director Granted 8,333 Stock Option (right to buy)
21 Jun 2022	Form 4/A: Callori Fred, Director Granted 8,333 Stock Option (right to buy)
04 Jan 2019	Form 4/A: Lapointe Anthony Gregg, Director Granted 2,800 Stock Option (right to buy)
13 Sep 2016	Form 4/A: Cunnane Deirdre A., SVP, General Counsel Granted 45,000 Stock Option (right to buy)
13 Sep 2016	Form 4/A: Modi Rick, Chief Business Officer Granted 45,000 Stock Option (right to buy)
13 Sep 2016	Form 4/A: Donovan Joanne M., CMO; SVP Clinical Development Granted 45,000 Stock Option (right to buy)
13 Sep 2016	Form 4/A: Milne Jill C., Director Granted 45,000 Stock Option (right to buy)

Comments